# 关于Chad Spooner 2025年5月，美敦力宣布计划将其糖尿病业务分拆为一家独立的、公开上市的公司，预计在 18个月内 完成分 离。MiniMed将继承美敦力在糖尿病管理领域的创新传统， 专注于提供完整的胰岛素管理系统，包括自动胰 岛素泵、连续血糖监测仪（CGM）和智能胰岛素笔等产品 。 2025年7月8日， Medtronic（美敦力） 宣布， Chad Spooner将于2025年7月14日起正式出任其糖尿病业 务部门 MiniMed 的首席财务官（CFO） 。此次任命正值Medtronic计划将糖尿病业务分拆为一家独立上市公 司之际，旨在为该业务板块的独立运营和未来发展奠定财务与战略基础。 Chad Spooner 拥有超过25年的财务领导经验，横跨医疗、消费品和工业领域，具备丰富的企业转型、财务 战略和资本市场运作经验。以下是其关键职业经历： 高管评价 BIC集团（BIC Group）CFO ：在加入Medtronic之前，Spooner担任全球消费品公司BIC的 首席财务 官 ，负责全球财务战略、投资者关系及企业并购事务。 Tenex Capital Management ：他曾联合创办 ...

GALWAY, Ireland, July 8, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the appointment of Chad Spooner as chief financial officer (CFO) of MiniMed, in advance of its intended separation into a standalone, public company. Effective July 14, 2025, Chad will be responsible for overseeing the Finance function for Medtronic Diabetes and supporting initiatives aimed at accelerating profitable growth and delivering shareholder value as it prepares to beco ...

内容概要：PTCA球囊，即Percutaneous Transluminal Coronary Angioplasty Balloon，全称为经皮冠状动 脉腔内成形术球囊，是一种用于心血管介入治疗的医疗器械。随着心血管病患病人口数持续增加，冠脉 介入治疗手段不断普及，基层医院快速发展、国家组织器械耗材带量采购以及国产医疗器械崛起，我国 PTCA球囊扩张导管行业市场规模稳步扩大。数据显示，2024年，我国PTCA球囊扩张导管行业规模已 从2021年的10.59亿元增长至13.66亿元；根据市场预测，至2030年有望突破至22.74亿元。 相关上市企业：波士顿科学（BSX）；美敦力（MDT）；先瑞达医疗-B（06669）；业聚医疗 （06929）；微创医疗（00853）；蓝帆医疗（002382）；乐普医疗（300003）；归创通桥（02190）； 赛诺医疗（688108）；惠泰医疗（688617）等 一、行业概况 PTCA球囊，即Percutaneous Transluminal Coronary Angioplasty Balloon，全称为经皮冠状动脉腔内成形 术球囊，是一种用于心血管介入治疗的医疗器械，主要 ...

招商通知 第三届全球手术机器人大会 第二届全球医疗科技大会 2025年7月1日， 美敦力（Medtronic） 宣布了一项人事任命。现任 碧迪医疗（BD）高级副总裁、总法律顾问 Michelle Quinn（米歇尔·奎因） ，接替即将退休的 Ivan Fong ，出任美敦力高级副总裁、总法律顾问兼公司 秘书。该任命将于2025年7月21日正式生效。 此项任命，正值美敦力深处战略转型的重要阶段。随着全球医疗器械行业面临日益复杂的监管环境与创新竞 争，美敦力此举被视为在法律与合规领域的一次关键布局。 # I v a n F o n g ： 前 任 背 景 与离任 她毕业于科尔盖特大学，获得政治学学士学位，随后取得维拉诺瓦大学法学博士（Juris Doctor）学位，为其职 业生涯奠定了坚实的法律基础。 曾任 3M 首席法律与政策官 曾任美国国土安全部总法律顾问 曾任 Cardinal Health 首席法律官 此次人事更迭，也标志着 Ivan Fong 在美敦力的阶段性告别。 Ivan Fong 自 2022 年加入美敦力以来，一直担任高级副总裁、总法律顾问兼公司秘书，领导美敦力全球法律事 务。他的职业履历同样卓 ...

Core Insights - Dividend yield is a key metric for identifying dividend stocks, reflecting the amount of a company's dividend as a percentage of its stock price, which can fluctuate daily [1] - A strong balance sheet, indicated by a low debt-to-equity ratio, is essential for long-term dividend sustainability [2][3] Company Summaries Costco - Costco has a dividend yield of 0.53% with an annual dividend of $5.20 and a 22-year track record of dividend increases [5] - The company has delivered a total return of over 266% over the past five years, with a debt-to-equity ratio of 0.21%, indicating strong financial health [6] - Investors should focus on the 12.7% average dividend growth over the last three years rather than the current yield [7] Archer-Daniels-Midland (ADM) - ADM boasts a dividend yield of 3.86% with an annual dividend of $2.04 and a 53-year history of dividend increases [8] - The company's debt-to-equity ratio stands at 0.34%, suggesting a stable dividend outlook [8] - However, ADM's growth is closely tied to commodity prices, which are cyclical, making it less defensive compared to consumer staples [9] Medtronic - Medtronic has a dividend yield of 3.26% with an annual dividend of $2.84 and a 49-year history of dividend increases [11] - The company is well-positioned in the aging population market and in AI and machine learning, with a debt-to-equity ratio of around 0.53% [12][13] - Despite its potential, Medtronic is not currently highlighted as a top buy by analysts, indicating some caution among investors [14]

Company Performance - Medtronic's stock increased by 1.34% to $87.17, outperforming the S&P 500's gain of 0.52% [1] - Over the past month, Medtronic's stock has risen by 3.66%, while the Medical sector gained 1.88% and the S&P 500 increased by 4.27% [1] Upcoming Earnings - Medtronic's earnings report is expected on August 19, 2025, with an anticipated EPS of $1.23, indicating no change from the same quarter last year [2] - Revenue is projected to be $8.37 billion, reflecting a 5.69% increase compared to the same quarter last year [2] Fiscal Year Projections - For the entire fiscal year, earnings are projected at $5.55 per share and revenue at $35.29 billion, representing increases of 1.09% and 5.23% respectively from the prior year [3] Analyst Forecasts - Recent revisions to analyst forecasts for Medtronic should be monitored, as they reflect short-term business trends [4] - Positive estimate revisions are interpreted as a favorable sign for the business outlook [4] Zacks Rank and Valuation - The Zacks Rank system currently rates Medtronic as 5 (Strong Sell), with a 0% increase in the EPS estimate over the last 30 days [6] - Medtronic has a Forward P/E ratio of 15.51, which is lower than the industry average of 19.12 [7] - The company has a PEG ratio of 2.32, compared to the industry average PEG ratio of 2.25 [7] Industry Context - The Medical - Products industry has a Zacks Industry Rank of 155, placing it in the bottom 37% of over 250 industries [8] - Research indicates that the top 50% rated industries outperform the bottom half by a factor of 2 to 1 [8]

Moretus Research delivers state-of-the-art, buy-side quality equity research for serious investors seeking clarity, conviction, and alpha. Focused on U.S. public markets, Moretus applies a structured, repeatable framework to identify companies with durable business models, mispriced cash flow potential, and intelligent capital allocation. Built on institutional standards, Moretus Research combines rigorous fundamental analysis with a high-signal, judgment-driven process—eschewing noise, narrative, and overl ...

Group 1 - The S&P 500 reached a new record high, surpassing its previous peak from February [1] - The top-performing sectors include Tech, Industrials, and Financials, while the Health Care sector has underperformed [1] Group 2 - The article emphasizes the importance of analyzing stock market sectors, ETFs, and economic data to identify investment opportunities [1]

Key Takeaways BSX gains MedSurg share via growth in Endoscopy, Urology and Neuromodulation product lines. MDT expands Surgical Robotics with Hugo RAS, now rolled out across 30 international markets. Both BSX and MDT see growth in emerging markets. Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are ...

GALWAY, Ireland, June 23, 2025 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced that its Board of Directors appointed Dr. Joon Lee, CEO at Emory Healthcare, Inc., to the Board as an independent director, effective June 18, 2025. Dr. Lee will serve on the Science and Technology Committee and Compensation and Talent Committee of the Board."We are thrilled to welcome Dr. Lee, a highly respected interventional cardiologist and healthcare executive, to Medtroni ...